Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Twist Bioscience Corporation (NASDAQ: TWST) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a mid-cap growth and value biotech company focused on synthetic DNA tools and a silicon-based DNA synthesis platform, Twist uses its filings to report financial performance, governance changes and other material events.
Investors can review current and historical 8-K reports, which for Twist have included announcements of quarterly and full-year financial results, as well as board and committee changes. For example, recent 8-K filings describe the release of financial results for specific quarters and fiscal years, and the appointment of a new director to the board and audit committee, along with associated compensation arrangements.
In addition to 8-Ks, users can access Twist’s annual reports on Form 10-K and quarterly reports on Form 10-Q via the SEC feed. These documents typically contain detailed discussions of results of operations, risk factors, and business descriptions related to Twist’s synthetic DNA platform, research tools and geographic operations. Proxy materials and equity compensation plan disclosures can also be reviewed to understand governance practices and incentive structures.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, helping readers quickly interpret complex documents such as lengthy 10-Ks or detailed 10-Qs. Real-time updates from EDGAR ensure that new filings appear promptly, while Form 4 and related insider transaction reports can be monitored to see equity awards and other reportable insider activity. Together, these resources support a deeper understanding of TWST’s regulatory disclosures and corporate developments.
TWST shareholder Paula Green filed a Rule 144 notice to sell 1,194 shares of common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $55,611.15, when 61,311,704 shares were outstanding and the approximate sale date listed as 02/03/2026.
The shares to be sold were acquired on 02/02/2026 via restricted stock vesting from the issuer as compensation. Over the prior three months, Green reported four separate common stock sales between 11/03/2025 and 12/22/2025. By signing, she represents she is not aware of undisclosed material adverse information about the issuer.
Twist Bioscience insider plans to sell common stock under Rule 144. Dennis H. Cho filed a notice to sell 1,099 common shares through Fidelity Brokerage Services on NASDAQ around 02/03/2026, with an aggregate market value of $51,186.47. The issuer has 61,311,704 common shares outstanding.
The 1,099 shares to be sold were acquired on 02/02/2026 via restricted stock vesting from the issuer as compensation. Over the past three months, Cho has sold additional common shares: 1,019 shares for $32,688.91 on 11/03/2025, 757 shares for $20,063.15 on 11/21/2025, 398 shares for $13,085.28 on 12/08/2025, and 324 shares for $11,196.14 on 12/22/2025.
An insider of the company trading under symbol TWST has filed a Rule 144 notice to sell 5,001 shares of common stock through Fidelity Brokerage Services LLC on or about 02/03/2026 on the NASDAQ, with an aggregate market value listed as $232,924.08.
The 5,001 shares were acquired on 02/02/2026 via restricted stock vesting from the issuer as compensation. The filer also reports prior sales in the last three months, including 4,887 common shares sold on 11/03/2025 for gross proceeds of $156,772.03. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer.
Twist Bioscience Corporation disclosed that investment manager Artisan Partners and related entities filed an amended Schedule 13G reporting a sizable passive stake. The group reports beneficial ownership of 5,830,205 shares of Twist common stock, or 9.5% of the class, based on 61,273,653 shares outstanding as of 12/26/2025.
Artisan entities report no sole voting or dispositive power. They share voting power over 4,959,392 shares and share dispositive power over 5,830,205 shares, held on behalf of discretionary clients of Artisan Partners Limited Partnership. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Twist Bioscience.
Twist Bioscience Corp reported a significant shareholder update as of December 31, 2025. ARK Investment Management LLC and its founder Catherine D. Wood together beneficially own 7,559,495 shares of Twist common stock, representing 12.36% of the outstanding class.
ARK holds sole voting power over 7,091,113 shares and sole dispositive power over all 7,559,495 shares. Catherine Wood has shared voting power over 7,227,245 shares and shared dispositive power over 7,559,495 shares, reflecting her control role at ARK.
The filing states that these securities were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing control of Twist Bioscience, and not in connection with any control-related transaction. ARK also notes that its client ARK Innovation ETF has an interest in more than 5% of the reported securities.
Twist Bioscience reported quarterly revenue of $103.7 million for the three months ended December 31, 2025, up 16.9% from $88.7 million a year earlier. Growth came from both DNA synthesis and protein solutions and NGS applications, with particularly strong demand from therapeutics and global supply partners.
Gross margin improved to 52.0% from 48.3% as higher volume and process improvements offset cost increases. The company still recorded a net loss of $30.5 million, slightly better than the $31.6 million loss last year, and used $24.8 million in operating cash.
Cash, cash equivalents and short-term investments totaled $197.9 million, and management believes this balance is sufficient to fund operations for at least one year. Operating expenses shifted, with lower research and development spending and higher selling, general and administrative costs to support commercial scaling.
Twist Bioscience Corporation filed a current report to note that it issued a press release announcing its financial results for the quarter ended December 31, 2025. The press release, titled “Twist Bioscience Reports Fiscal First Quarter 2026 Financial Results”, is furnished as Exhibit 99.1.
The company states that the information in this report, including Exhibit 99.1, is being furnished rather than filed under the Securities Exchange Act of 1934 and is not automatically incorporated by reference into Securities Act registration statements unless specifically referenced.
Twist Bioscience Corp's President and COO, Patrick John Finn, reported a small mandatory share sale related to equity compensation. On 01/23/2026, he sold 2,390 shares of common stock at $44.908 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units under the company's equity incentive plans and are described as non-discretionary trades. Following this transaction, he beneficially owned 310,493 shares of Twist Bioscience common stock directly.
An affiliate of TWST has filed a Rule 144 notice to sell 2,390 shares of common stock, with an aggregate market value of 107,329.41, through Fidelity Brokerage Services on NASDAQ around 01/23/2026.
These shares were acquired on 01/22/2026 via restricted stock vesting from the issuer as compensation. The filing also shows that Patrick Finn has sold multiple blocks of common stock over the past three months, including 23,279 shares on 01/13/2026 for gross proceeds of 931,160.00.
Twist Bioscience Corp’s Chief Financial Officer, Adam Laponis, reported a planned sale of company stock. On 01/13/2026, he sold 3,000 shares of Twist Bioscience common stock at a price of $40 per share. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan that he adopted on May 8, 2025, which is designed to allow insiders to sell shares according to a preset schedule. After this sale, Laponis directly beneficially owned 137,031 shares of Twist Bioscience common stock.